Full Press Release Details
SAN FRANCISCO, Nov. 11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in two upcoming investor conferences.
• UBS Global Biopharma Conference
• Format: Fireside Chat and 1x1 meetings
• Fireside Chat Date: Tuesday, November 17, 2026
• Fireside Chat Time: 11:20 – 11:50 a.m. GMT
• Location: London, UK
• Jefferies Global Healthcare Conference
• Format: Fireside Chat and 1x1 meetings
• Fireside Chat Date: Wednesday, November 18, 2026
• Fireside Chat Time: 8:00 – 8:25 a.m. GMT
• Location: London, UK
The live and archived webcasts will be accessible from the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events and replays will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
For Investors:
Vivian Wu 628-895-0661 VWu@nektar.com
Corey Davis, Ph.D. LifeSci Advisors 212-915-2577 cdavis@lifesciadvisors.com